THE WINTER PRESSURE REALITY IN COMMUNITY AND URGENT CARE
Winter pressure is predictable. What changes is the level of diagnostic uncertainty at first contact and how long that uncertainty persists before confirmation and appropriate management. In unscheduled community and primary care, winter pressure arrives as a sharp increase in demand that exceeds resources, which results in service wide anxiety and increased time constraints. ARIs are persistently the highest contributing factor to this winter surge, with people frequently presenting with undifferentiated cough, fever, sore throat, fatigue, or breathlessness symptoms; with most cases being safe to manage conservatively and in their own home. However, these overlapping symptoms are problematic features in young infants or those with co-morbidities and chronic health problems; they are at higher risk of developing severe symptoms and potentially risk requiring hospital admission. “The challenge is that the early clinical picture often looks similar across ARIs, and the system sometimes behaves as if the safest option is admission to hospital.”
NHS England has been clear that urgent community care should support safe decision making outside hospital with proper governance to support risk balanced decision making, rather than diversion to acute settings with fear of error. In earlier roles as a consultant advanced clinical practitioner in primary and urgent care, and Head of clinical performance, I saw the same mechanism repeat each winter. When diagnostic certainty is delayed or undifferentiated, clinicians become more risk averse, safety netting becomes more conservative or primed for escalation, or referrals increase, and the system pays for that uncertainty downstream with an increased burden in conveyances and admissions. Be assured, this is not a criticism of clinical caution or risk stratification. It is an observation about clinical governance, resources and pathway design. Winter resilience is increasingly defined by how quickly clinicians can make a decision, reduce uncertainty, while gatekeeping the community front door. Organisations are now formalising the shift to community, bringing digitally enhanced care closer to the patient. Whereas recent discussions within point-of-care patient testing, diagnostics and infectious disease groups, they have prioritised rapid community testing as a practical response to winter respiratory pressures, reflecting a broader move towards structured, pathways embedded with supported decision making – especially outside the hospital.
WHY RESPIRATORY DIAGNOSTICS IMPACT PATIENT FLOW, EVEN OUTSIDE HOSPITAL
Respiratory diagnostics can determine patient flow because they robustly confirm the working differential diagnosis, to support clinical risk stratification and management. If we cannot stratify early, we cannot confidently choose the lowest safe setting without risk, and the safest decision sometimes defaults to higher acuity settings. Delayed testing, or centralised testing with longer turnaround, increases time to decision and can increase the probability of an acute admission. The NHS England driver and guidance for ARI hubs, recognises that ARI is a major driver of emergency attendance and winter pressure. The guidance sets out models designed to increase assessment capacity and smooth patient journeys across primary, community, and secondary care. Interestingly, the NHSE urgent community care: clinical decisionmaking frameworks for managing acute respiratory illness in the community suggest POCT C-reactive protein (CRP) pathways but does not include the utility of rapid respiratory diagnostics for differentiating pathogen specific diseases that would inform targeted antivirals or antibiotics. However, the guidelines for integrating invitro POCT into pathology supported systems and services could encourage adoption but there is a misalignment to disease specific guidelines. UKHSA influenza guidance is explicit that influenza like illness is a clinical syndrome and that diagnosis can be challenging when other respiratory viruses co circulate. That matters most because winter decisions are influenced when symptoms overlap or where diagnostic delay increases risk or inappropriate treatment. From a clinical performance perspective, time to decision is a high leverage measure. If a patient can receive a timely, validated answer and a safe plan, the system reduces unnecessary escalation. From a patient perspective, time to decision is experienced as clarity, confidence, and continuity, rather than repeated contacts and conflicting advice or treatment.
POINT-OF-CARE TESTING AS A DECISION INFRASTRUCTURE
Point-of-care testing only creates value when it functions as a decision infrastructure. In winter, the goal is to reduce uncertainty early enough to change management, isolate early, and improve clinical pathway decisions. That is why ARI resilience is relevant. The published work on ARI hubs describes benefits that come from pathway design, standardised infection management, and separation of cohorts, not from testing alone. In community urgent care, the key decisions are often discharging home with robust safety netting, and additional support, follow-up, or escalation for acute review. In acute settings, the key decisions include streaming, cohorting, and admission versus discharge with or without treatment or follow-up. Testing needs to sit where a decision changes the disposition, not somewhere that is just technically available.
A LINKED WINTER PATHWAY MODEL ACROSS COMMUNITY AND ACUTE CLINICAL SETTINGS
I do not see winter preparedness as a single setting problem; I see it as an architectural interface problem. If community services are left managing uncertainty, without timely diagnostics and clear escalation routes, community care becomes a feeder into the acute front door. This is not theoretical. Community hub models for rapid test-andtreat respiratory pathways is positively represented through regional innovation programmes, with emphasis on real world evidence to support adoption and consistent implementation. However, if the acute front door is not designed to handle respiratory surges with rapid risk stratification and cohorting, it becomes congested, and the risk increases for everyone. NHS England ARI hubs guidance supports building on existing infrastructure to create models that manage demand in winter and beyond and improve the interface across all clinical settings.
A PRACTICAL LINKED PATHWAY HAS THREE COMPONENTS
1. Community and primary care act as early decision points using standardised assessment, red flag criteria, and aligned escalation thresholds.
2. The acute front door uses a designated respiratory assessment area or flow back into the community, aligned to ARI hub principles, so that likely ARIs can be assessed in a space or place designed for rapid decisions and reduced mixing.
3. A combination of pathology, microbiology and virology supported governance. The value is not case-by-case approval, it is defining testing policies, interpretation and record standards, and escalation thresholds that remain consistent during co-circulation of disease and operational pressure. UKHSA antiviral guidance also emphasises that clinicians should use national recommendations alongside specialist advice and local infection pathways, which fits well with a governance supported oversight model.
TURNING RESULTS INTO ACTION IN INFLUENZA SEASON
A result matters only if it changes what happens next which positively impacts patient outcomes. UKHSA provides national guidance on antiviral treatment and prophylaxis for seasonal influenza, with annually updated recommendations and an explicit recognition that clinical diagnosis can be challenging when other viruses co-circulate. This is why rapid confirmation of a disease can be valuable when embedded within a defined clinical management or diagnostic pathway when combined with clinical judgement or infectious disease specialist advice. Rapid diagnostics support timely treatment decisions for eligible cohorts and reduce unnecessary treatment plans, such as cautionary antibiotics in the presence of influenza-like symptoms or prevent antibiotic prescriptions with delayed dispensing in a more likely probability of viral pathogen causes for acute sore throat presentations. It can also support infection prevention and control decisions, especially when ARIs continue to drive demand across the systems. All while supporting patient trust in decision making, preventing them seeking additional opinions in A&E. In urgent and primary care, this translates into validated management and discharge decisions when safe to do so, and earlier escalation when there are signs of decline or deterioration. The operational benefit is fewer precautionary referrals. The clinical benefit is a decision that is robustly quantified, transparent, and more consistent. The patient benefit is a plan that is clearer, with focused safety netting and appropriate treatment delivered sooner.
WHY EMBEDDING POINT-OF-CARE TESTING IS CHALLENGING IN COMMUNITY CARE
In my experience, funding remains a primary barrier, often due to misalignment between commissioning scope, provider readiness, and access to time-limited funding mechanisms. Programmes fail in delivery less often because of analytical performance but more often because the system does not resolve the key practical issues: ownership, workforce, estates, digital integration, and governance; but moreover, a lack of agile funding and redistribution.
“One consistent implementation lesson is that enthusiasm is rarely the limiting factor” Adoption tends to accelerate when system-wide operational and clinical leaders can point to real world evidence from comparable services showing pathway impact on decisions, flow, and escalation. I would debate that commissioners and governing bodies prefer the most cost-effective community models. Subsequently, this creates overly complex programme expectations, often spanning outcomes, flow, access, and system efficiency, which can dilute implementation and focus. NHS England urgent community care guidance is explicit that safe out of hospital care depends on effective governance and appropriate clinical decision making. Ownership ambiguity is therefore not a minor operational issue; it is a governance risk. 1. O wnership is the first challenge. Who owns quality and training? Who owns the pathway decisions? Who owns the operational response when demand surges? Without clear ownership, practice becomes variable, and confidence in the deployment erodes. 2. Workforce challenges. Staffing is continually under pressure in winter. Skill mix changes. Inexperienced staff rotate in. Sustaining competency and consistent actions requires a clear training model, time to develop skills, defining roles or scope of practice, and escalation rules that work in hours, as well as evenings and weekends. 3. Estates and infection control constraints. Safe sampling, patient separation, and clean workflows are easier to describe than to deliver in crowded environments. UKHSA emphasises proportionate, risk based, time limited interventions to protect wellbeing while managing outbreaks. The principle applies in clinical estates too. We need practical workflows that reduce mixing without creating bottlenecks. 4. Digital integration and architecture challenges. A respiratory result that does not reliably appear in the patient clinical record becomes a latent patient safety and/or governance risk because it cannot be easily audited or captured automatically, and it cannot support continuity when patients re-present to healthcare settings. This is not optional. It is part of safe pathway design. 5. Timing and motivation is a recurrent challenge. If winter pathway design begins when the surge has already arrived, the system will default to the safest looking option, which often becomes conveyance and admission.
WHAT TO MEASURE IF WE WANT TO LEARN AND SCALE
If a winter respiratory pathway is working, the measures should reflect both patient experience and system performance.
- Time to decision: This is the mechanism. If time to decision does not improve, the pathway is not reducing uncertainty.
- Escalation and conveyance rate from community UTC for influenza like illness presentations: This tests whether uncertainty is being resolved earlier. Admission rates and reasons for escalation: This tests whether escalation clarity and early disease recognition pathways are improving.
- Record completeness and result visibility: This tests governance and safety.
These measures align with the intent of urgent care, ARI hub models and urgent community care decision frameworks, which depend on reliable decision making and safe governance across interfaces.
PRACTICAL TAKEAWAYS FOR WINTER PLANNING
Start pathway design while the winter headache remains - in early spring and finalise at the end of summer, not during the upslope of a surge.
Design point of care testing around decisions and place it where it changes disposition.
Agree ownership across urgent care, pathology governance, IPC, and virology for thresholds and escalation rules.
Ensure results land reliably in the clinical record so decisions are auditable, and continuity is protected.
SUMMARY
Winter resilience is no longer defined by capacity alone but by the speed and reliability of clinical decision-making across system interfaces. Embedding rapid diagnostics as decision infrastructure enables earlier risk stratification, reduces avoidable escalation, and strengthens governance across urgent and acute pathways. Without this shift, services will continue to default to risk-based escalation under uncertainty, perpetuating avoidable pressure on emergency care.
References
NHS England, 2023. https://www.england.nhs.uk/long-read/integrating-invitro-point-of-care-diagnostics-guidance-for-urgent-community-response-andvirtual-ward-services/ (Accessed 8th May 2026).
NHS England, 2024. https://www.england.nhs.uk/long-read/combined-adultand-paediatric-acute-respiratory-infection-ari-hubs/ (Accessed 8th May 2026).
NHS England, 2026. https://www.england.nhs.uk/publication/urgentcommunity-care-clinical-decision-making-framework/ (Accessed 8th May 2026).
UK Health Security Agency, 2024. https://www.gov.uk/government/ publications/acute-respiratory-disease-managing-outbreaks-in-care-homes (Accessed 8th May 2026).
UK Health Security Agency, 2024. https://www.gov.uk/government/ publications/acute-respiratory-disease-managing-outbreaks-in-care-homes/ management-of-acute-respiratory-infection-outbreaks-in-care-homesguidance (Accessed 8th May 2026).
UK Health Security Agency, 2026. https://www.gov.uk/government/ publications/influenza-treatment-and-prophylaxis-using-anti-viral-agents/ guidance-on-use-of-antiviral-agents-for-the-treatment-and-prophylaxis-ofseasonal-influenza (Accessed 8th May 2026).
UK Health Security Agency and Department of Health and Social Care, 2025. https://www.cas.mhra.gov.uk (Accessed 8th May 2026).
RDx-26002645 | 08/26
